Navigation Links
Shimadzu's New DSC-60 Plus Series Differential Scanning Calorimeters Offer High-Sensitivity Analysis in Polymer, Food and Pharmaceutical Applications
Date:4/18/2013

Columbia, Maryland (PRWEB) April 18, 2013

Shimadzu Scientific Instruments has introduced the DSC-60 Plus Series differential scanning calorimeters, indispensable thermal analyzers for materials characterization. The DSC-60 Plus Series offers the high-sensitivity analysis and easy operation required for the development of high-functioning new materials in the food, polymer and pharmaceutical industries.

As high-performance, general-purpose differential scanning calorimeters, the DSC-60 Plus Series offers high sensitivity and high resolution during analysis. Its new detector and unique furnace construction achieve a stable baseline across the entire measured temperature range (-140 to 600° C), as well as top-class temperature sensitivity. The eco-friendly furnace achieves more than 20 percent lower energy consumption when heating from room temperature.

A cooling chamber comes installed as standard on the DSC-60 Plus Series. The liquid-nitrogen cooling chamber permits easy measurements without the need for special accessories. Further, it achieves a cooling rate of 10° C/minute at -100° C. Its sample loading temperature function enables quick sample change without dewfall during sequential analysis.

The DSC-60A Plus model features a built-in compact autosampler, which permits automated measurement, analysis and report printout for up to 24 loaded samples. It improves the efficiency of screening during product development, as well as the efficiency of quality control activities.

Additionally, the DSC-60 Plus Series complies with various analytical laboratory regulations, including the U.S. Food and Drug Administration’s 21 CFR Part 11.

For more information about the DSC-60 Plus Series, visit http://www.ssi.shimadzu.com/products/product.cfm?product=dsc60Plus.

About Shimadzu Scientific Instruments Inc.
Shimadzu Scientific Instruments (SSI) is the American subsidiary of Shimadzu Corp., headquartered in Kyoto, Japan. Founded in 1875, Shimadzu is a $3 billion multinational corporation with three major divisions: Medical Diagnostics, Aerospace/Industrial and Analytical Instruments. In the United States, SSI has a network of more than 50 locations providing local and regional sales, service and technical support. Visit http://www.ssi.shimadzu.com for more information.

###

Read the full story at http://www.prweb.com/releases/2013/4/prweb10650226.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
2. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
3. InnoPharma Completes $15 Million Series A Financing
4. Aratana Therapeutics Completes $15 Million Series B Financing
5. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
6. Roka Bioscience Secures $47.5 Million in Series D Financing
7. Auxogyn Completes $20 Million In Series A Funding
8. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
9. NeuroPhage Extends Series B to $21.4M
10. Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin
11. Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
Breaking Biology Technology:
(Date:8/15/2017)... LLC , a medical device company focused on improving the safety ... ISO 13485 Certification, the global standard for medical device quality management ... ... for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it validates our ...
(Date:6/23/2017)... and ITHACA, N.Y. , ... and Cornell University, a leader in dairy research, today ... bioinformatics designed to help reduce the chances that the ... the onset of this dairy project, Cornell University has ... for Sequencing the Food Supply Chain, a food safety ...
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
Breaking Biology News(10 mins):